Joseph Lim, MD
Professor of MedicineDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Clinical Hepatology, Digestive Diseases
Vice-Chief of Hepatology, Section of Digestive Diseases, Digestive Diseases
Director, Yale Viral Hepatitis Program
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), P.O. Box 208019
New Haven, CT 06520-8019
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Clinical Hepatology, Digestive Diseases
Vice-Chief of Hepatology, Section of Digestive Diseases, Digestive Diseases
Director, Yale Viral Hepatitis Program
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), P.O. Box 208019
New Haven, CT 06520-8019
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Clinical Hepatology, Digestive Diseases
Vice-Chief of Hepatology, Section of Digestive Diseases, Digestive Diseases
Director, Yale Viral Hepatitis Program
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), P.O. Box 208019
New Haven, CT 06520-8019
United States
About
Titles
Professor of Medicine
Director, Clinical Hepatology, Digestive Diseases; Vice-Chief of Hepatology, Section of Digestive Diseases, Digestive Diseases; Director, Yale Viral Hepatitis Program
Appointments
Digestive Diseases
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Stanford University Medical Center (2005)
- Resident
- Yale-New Haven Hospital (2002)
- Intern
- Yale-New Haven Hospital (2000)
- MD
- Northwestern University Medical School (1999)
Research
Overview
I would be pleased to work with trainees and scientists who are interested in studying health outcomes in patients with chronic liver disease, with particular attention to chronic hepatitis B and C infections, fatty liver disease, liver cirrhosis and complications of portal hypertension, and hepatocellular carcinoma. I am an investigator in several national or international multicenter cohort studies evaluating health outcomes focused on hepatitis B and hepatitis C therapy, and a VA cohort study evaluating liver disease outcomes in patients with or without HIV coinfection.
Medical Research Interests
Carcinoma, Hepatocellular; Clinical Trial; Delivery of Health Care; Fatty Liver; Health Services Research; Hepatitis B; Hepatitis C; Hepatitis D; Liver Cirrhosis; Liver Neoplasms; Quality of Health Care
Public Health Interests
Hepatitis
ORCID
0000-0001-7399-5756- View Lab Website
Yale Viral Hepatitis Program
Research at a Glance
Yale Co-Authors
Frequent collaborators of Joseph Lim's published research.
Publications Timeline
A big-picture view of Joseph Lim's research output by year.
Research Interests
Research topics Joseph Lim is interested in exploring.
Basile Njei, MD, PhD, MPH, FACHDM
Albert Do, MD, MPH
Amy Justice, MD, PhD
Tamar Taddei, MD
Bubu Banini, MD, PhD
Christopher T Rentsch, PhD, FISPE
53Publications
4,689Citations
Liver Cirrhosis
Liver Neoplasms
Carcinoma, Hepatocellular
Hepatitis B
Hepatitis C
Fatty Liver
Publications
2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitisHepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among U.S. Veterans with Chronic Hepatitis B. Gastro Hep Advances 2024 DOI: 10.1016/j.gastha.2024.10.015.Peer-Reviewed Original ResearchConceptsChronic hepatitis B patientsChronic hepatitis BLiver-related outcomesHepatic decompensationHepatitis delta virusCohort of U.S. veteransNational cohortU.S. veteransRisk of cirrhosisIncidence of cirrhosisPositive patientsHDV infectionHepatitis BEvaluate incidenceHepatocellular carcinomaCirrhosisPatientsDecompensationVirus testingPropensity scoreHepatitisDelta virusNelson-Aalen methodDiagnosisOutcomesOutcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B
Wong R, Liao M, Chen Y, Kwan M, Lee J, Jou J, Lim J, Cheung R. Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B. Journal Of Viral Hepatitis 2024, 31: 768-770. PMID: 39101377, DOI: 10.1111/jvh.13992.Peer-Reviewed Original ResearchConceptsChronic hepatitis BAnti-HDVRNA testingHepatitis delta virusVeterans Affairs Health SystemUniversal testing approachAnti-HDV-positive patientsPilot studyChronic hepatitis B patientsProspective cohort studyHDV-RNA testsAnti-HDV antibodiesConsecutive CHB patientsRisk-based testingHealth systemDetectable HDV RNAChi-square testUS veteransDrug use historyCohort studyCirrhosis statusCHB patientsConsecutive adultsNo significant differenceAb positivitySevere Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceAssociation of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma
Yang Z, Cheung R, Jou J, Lim J, Lim Y, Wong R. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma. Gastroenterology Research 2024, 17: 109-115. PMID: 38993547, PMCID: PMC11236339, DOI: 10.14740/gr1735.Peer-Reviewed Original ResearchConceptsBaseline HBV DNARisk of hepatocellular carcinomaChronic hepatitis BRisk of cirrhosisNon-cirrhotic chronic hepatitis BHepatitis B virus DNAHBV DNAHepatocellular carcinomaHepatitis B virusCHB patientsPropensity score weightingAntiviral therapyAssociated with higher risk of hepatocellular carcinomaHigh risk of hepatocellular carcinomaNon-cirrhotic CHB patientsCohort of CHB patientsLevels of hepatitis B virusContinuous antiviral therapyHigh HBV DNANon-Asian cohortModerate levelsAssociated with higher riskScore weightingB virus DNACox proportional hazards modelsIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsFRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. FRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B. Journal Of Hepatology 2024, 80: s771. DOI: 10.1016/s0168-8278(24)02152-4.Peer-Reviewed Original ResearchEditorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
Njei B, Lim J. Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Alimentary Pharmacology & Therapeutics 2024, 60: 83-84. PMID: 38643498, DOI: 10.1111/apt.17951.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAn explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis
Njei B, Osta E, Njei N, Al-Ajlouni Y, Lim J. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Scientific Reports 2024, 14: 8589. PMID: 38615137, PMCID: PMC11016071, DOI: 10.1038/s41598-024-59183-4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNational Health and Nutrition Examination SurveyRisk of progression to cirrhosisClinical risk indexHealth and Nutrition Examination SurveyControlled attenuation parameter valuesNovel therapeutic optionsLiver stiffness measurementProgression to cirrhosisAspartate aminotransferase levelsNutrition Examination SurveyResource-limited settingsFIB-4Fibrosis scorePlatelet countAminotransferase levelsTherapeutic optionsWaist circumferenceClinically applicable modelExamination SurveyNonalcoholic steatohepatitisFAST scoreEarly identificationElastography measurementsStiffness measurementPatientsAdvances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
Lam R, Lim J. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World Journal Of Hepatology 2024, 16: 331-343. PMID: 38577537, PMCID: PMC10989302, DOI: 10.4254/wjh.v16.i3.331.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsFunctional cure of chronic hepatitis BCure of chronic hepatitis BNovel investigational agentsChronic hepatitis BFunctional cureHepatitis B virusInvestigational agentsHepatitis BSuppression of HBV DNARisk of liver complicationsChronic hepatitis B virusAssociated with significant morbidityToll-like receptor agonistsOral nucleos(t)ide analoguesHepatitis B surface antigenB surface antigenLong-term treatmentAssociated with higher ratesMortality due to cirrhosisCheckpoint inhibitorsNucleos(t)ide analoguesVirologic suppressionPhase IIAntiviral regimensIII trials
Clinical Trials
Current Trials
A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)
HIC ID2000030905RolePrincipal InvestigatorPrimary Completion Date02/28/2024Recruiting ParticipantsGenderBothAge18+ yearsMetabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
HIC ID2000027577RolePrincipal InvestigatorPrimary Completion Date11/01/2022Recruiting ParticipantsGenderBothAge18 years - 75 years
Academic Achievements & Community Involvement
honor Howard M. Spiro Faculty Teaching Award
UnknownYale University School of MedicineDetails01/01/2009United States
Clinical Care
Overview
Clinical Specialties
Gastroenterology; Hepatology
Fact Sheets
Hepatitis B and C
Learn More on Yale MedicineInflammatory Bowel Disease
Learn More on Yale MedicineRectal Bleeding
Learn More on Yale MedicineColorectal Polyps
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- November 08, 2024
Liver Cancer Screening: A New Tool for Improved Detection
- August 03, 2024
Addressing Behavioral Health in Patients With End-stage Liver Disease
- February 28, 2023
Dr. Joseph K. Lim Named Editor-in-Chief of Clinical Liver Disease
- January 08, 2023
Digestive Health Learning Series Back for 2023!
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Clinic Fax Number
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), P.O. Box 208019
New Haven, CT 06520-8019
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Jan 202514Tuesday
Yale Only Tai-Chung Tseng, MD
Feb 202521Friday
Yale Only Joseph Lim, MD